US Patent

US11633528 — Apparatus for removing chemotherapy compounds from blood

Method of Use · Assigned to Delcath Systems Inc · Expires 2032-11-07 · 6y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects an apparatus and method for removing chemotherapy compounds, such as melphalan hydrochloride, from blood.

USPTO Abstract

A filter apparatus for removing small molecule chemotherapy agents from blood is provided. The filter apparatus comprises a housing with an extraction media comprised of polymer coated carbon cores. Also provided are methods of treating a subject with cancer of an organ or region comprising administering a chemotherapeutic agent to the organ or region, collecting blood laded with chemotherapeutic agent from the isolated organ, filtering the blood laden with chemotherapeutic agent to reduce the chemotherapeutic agent in the blood and returning the blood to the subject.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3675 melphalan-hydrochloride

Patent Metadata

Patent number
US11633528
Jurisdiction
US
Classification
Method of Use
Expires
2032-11-07
Drug substance claim
No
Drug product claim
No
Assignee
Delcath Systems Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.